Successful therapy confirmed for newborns with fatal metabolic disorder MoCD type A

The drug fosdenopterin/rcPMP considerably improves the chances of survival and developmental progress in infants with molybdenum cofactor deficiency (MoCD type A), a rare and life-threatening genetic condition causing an inborn error in metabolism. This was shown in a clinical study recently published by an international research team led by Professor Dr. Günter Schwarz from the Institute of Biochemistry at the University of Cologne.

👉 Full Story